Reported Saturday, Johnson & Johnson's TAR-200 Monotherapy Demonstrates Strong Early Efficacy In BCG-Unresponsive Bladder Cancer, Achieving Over 80% Disease-Free Survival

First results from SunRISe-1 (Cohort 4) show strong disease-free survival rates across high-grade papillary tumors, demonstrating the potential for bladder preservation with 94 percent of patients avoiding radical cystectomy

95 percent progression-free survival rate at 9-months signals the promise of TAR-200 in this high-risk patient population